Author: Iterion Therapeutics

Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer

September 22, 2026
Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting

June 1, 2026

Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer